anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The preweaning period for a dairy calf is characterized by high morbidity and mortality rates, leading to financial losses for producers. Identifying strategies to improve the health and welfare of calves while reducing antimicrobial use continues to be crucial to the success of the dairy industry. The objective of this study was to determine the effects of feeding colostrum replacer (CR) to dairy heifer calves beyond d 1 of life on growth, serum IgG, the incidence of diarrhea and bovine respiratory disease (BRD), and the risk of mortality in the preweaning period. At birth, Holstein heifer calves (n = 200; 50/treatment) weighing 40.7 ± 0.35 kg (mean ± SE) were fed 3.2 L of CR (205 g IgG/feeding) at 0 h and 12 h of life. Calves were then randomly assigned to 1 of 4 treatments: 450 g of milk replacer (MR) from d 2 to 14 (control, CON), 380 g of CR + 225 g of MR from d 2 to 3, then 450 g of MR from d 4 to 14 (transition, TRAN), 45 g of CR + 450 g of MR from d 2 to 14 (extended, EXT); or 380 g of CR + 225 g of MR from d 2 to 3, then 45 g of CR + 450 g of MR from d 4 to 14 (transition + extended, TRAN+EXT). Each treatment was reconstituted to 3 L and fed twice daily. All CR treatments were fed using bovine-derived CR containing 27% IgG. From d 15 to 41, all calves were fed 600 g of MR reconstituted to 4 L twice daily. Body weight was recorded at birth and every 7 d until study completion on d 49. Blood samples were taken daily until d 7 to evaluate serum IgG and then every 7 d until d 49. A health assessment was performed daily to evaluate calves for BRD and diarrhea. Data were analyzed using mixed linear regression, mixed logistic regression, and survival analysis models in SAS 9.4. Serum IgG concentrations were not affected by treatment for the study period. The EXT and TRAN+EXT groups had greater average daily gain (ADG) from d 7 to 14 (0.14 kg/d) and the TRAN group had greater ADG from d 14 to 21 (0.11 kg/d), compared with CON. There was no association of treatment with the odds or the duration of a diarrhea bout. However, provision of CR to the TRAN and EXT calves was associated with a reduced hazard of diarrhea compared with CON calves. Furthermore, TRAN and EXT calves have a lower hazard of mortality compared with CON calves, with TRAN and EXT calves had a 2.8- and 3.8-times lower hazard of mortality, respectively. Our findings suggest that the supplementation of CR to dairy calves positively affects ADG, and reduces the hazard of diarrhea and mortality during the preweaning period. Future research should look to further refine the supplementation strategy of CR to calves and explore the mechanism of action.
To enter into the single-blind placebo phase, subjects will be setup with a Fisher \& Paykel 604 CPAP unit with a heated humidifier and "deactivated" Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still "appear" to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily.
PURPOSE: While the benefits of exercises for chronic obstructive pulmonary disease (COPD) are well-established, the relative effectiveness of different exercise types for stable COPD remains unclear. This network meta-analysis aims to investigate the comparative effects of aerobic exercise (AE), resistance training (RT), endurance training (ET), and high-intensity interval training (HIIT) in stable COPD.
METHODS: Electronic searches were performed in PubMed, Embase, and the Cochrane library to identify relevant randomized controlled trials (RCTs) investigating the effects of exercises on 6-minute walk test distance (6MWD), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC), and St. George's Respiratory Questionnaire (SGRQ) score. Two authors screened the retrieved articles, extracted relevant data, and assessed the risk of bias. Network meta-analysis was conducted using Stata 14.0.
RESULTS: This study included a total of 19 studies involving 951 patients with stable COPD. HIIT emerged as the most favorable exercise type for enhancing 6MWD, with a probability of 82.9%. RT exhibited the greatest efficacy in reducing SGRQ scores, with probability of 49.8%. Notably, ET demonstrated superiority in improving FEV1 and FVC, with probabilities of being most effective at 78.1% and 42.0%, respectively.
CONCLUSION: This study suggests that HIIT may be a viable intervention for improving exercise capacity in stable COPD patients, compared to AE, RR, and ET. RT may hold promise for improving quality of life, and ET may demonstrate superiority in improving pulmonary function. However, variation in response likely depends on patient characteristics, program parameters, and delivery context. Future research should explore the synergistic effects of combining RT with ET/HIIT, focusing on patient subgroups, optimal dosing, and settings, as current guidelines indicate this combination may offer the most significant benefits.
Endothelial dysfunction, assessed by measurement of brachial artery reactivity, is associated with coronary artery disease. Previous studies showed that patients taking HIV protease inhibitors (PIs) had a buildup of fatty deposits in their arteries and impaired flow-mediated vasodilation of the brachial artery, whereas endothelial function was normal in HIV-infected individuals not taking PIs. The effect of three different antiretroviral regimens on endothelial function in antiretroviral naïve HIV-infected patients will be examined in this substudy.

Patients in this substudy will have Brachial Artery Reactivity Tests (BARTs), which are painless ultrasound tests of an artery in the lower arm. Brachial artery reactivity will be measured at entry and at 4 and 24 weeks after patients are randomized to one of three open-label drug regimens in ACTG A5142. Brachial artery reactivity in response to two vasoactive stimuli (flow-mediated and nitroglycerin) will be assessed by measuring brachial artery diameter and flow velocity. Blood will be drawn at Weeks 4 and 24 for insulin and lipid tests. Patients will fast and refrain from tobacco and caffeine use for at least 8 hours prior to each study visit. For the duration of the substudy, patients will be asked not to change the amount of fruits, juices, antioxidants, and tea that they consume.
Participants will be submitted to an expository-dialogue class, which will be given based on the recent literature and subdivided into the following axes: 1) patient safety; 2) medication process; 3) adverse drug events; 4) the critical patient in intensive care and its specificities. Afterwards, students will be directed to an environment with an anatomical piece for drug preparation and administration training.
Cerebral palsy (CP) being a non-progressive neurodevelopmental condition, is the leading cause of chronic disability in children, making them physically and mentally handicapped and socially unapproachable. The low tone of the torso also causes postural instability, lack of mobility, and muscle stiffness in the legs. Therapeutic intervention for children with cerebral palsy should be composed of goal directed, functional, and meaningful activities by considering the clinical type, degree of disability, cognitive level and interest of the child. The trunk being the central key point of the body, proximal trunk control is a prerequisite for distal limb movement control, balance, and functional mobility. Since children with cerebral palsy show damage not only in the function and an ability to accomplish tasks, but also in the quality of movement. The objective of this study will be to help clinicians regarding the effectiveness of task-oriented training and gross motor functional training for children with cerebral palsy.

This will be a Randomized Clinical Trial in which participants of age 5 - 12 years with cerebral palsy will be assigned randomly for the study. Population will be taken from Physical Therapy Department of Agile Rehabilitation Complex, Bahawalpur. After taking consent, demographics including age, gender and birth history etc. will be recorded. Questionnaires will be distributed among parents and their responses will be collected. Questionnaires for trunk impairment scale, postural assessment scale, pediatric balance scale and GMFM-88 will be used as tools of assessment. The collected data will be analyzed in Statistical Package for the Social Sciences (SPSS) 27.0.
Fentanyl Citrate Injection is a Schedule II controlled drug substance and is an opioid agonist. Fentanyl Citrate Injection, USP is a sterile, clear, colorless, non-pyrogenic, preservative free aqueous solution for intravenous or intramuscular injection. 

Fentanyl Citrate Injection contains fentanyl citrate as the active pharmaceutical ingredient. The chemical name is N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide 2-hydroxy-1,2,3-propanetricarboxylate. The molecular weight is 528.60 g/mol. Its molecular formula is C22H28N2O • C6H8O7, and it has the following chemical structure: 

Each mL of Fentanyl Citrate Injection contains 78.5 mcg fentanyl citrate (equivalent to 50 mcg fentanyl base), sodium hydroxide (q.s.) as pH adjuster, in water for injection. Fentanyl Citrate Injection pH is between 4.5 to 7.0.
A sealing apparatus suitable for sealing a side of a panel element is provided. The sealing apparatus includes a supporting stage, a soft elastic element, a driving device and a force-applying element. The soft elastic element is disposed on the supporting stage. The driving device is disposed at the supporting stage. The force-applying element is connected to the driving device. When the panel element is put onto the supporting stage and the side is adjacent to the soft elastic element, the force-applying element pushes the soft elastic element by driving of the driving device, such that the soft elastic element is deformed for encapsulating the side tightly.
BACKGROUND: Compared with the general population, adults with an intellectual developmental disorder (IDD) are more likely to develop mental health problems and to receive high levels of psychotropic medication, particularly antipsychotics. The emotional development (ED) approach may help to better understand the nature of challenging behaviour (CB) and tailor treatment and support accordingly. The aim of this retrospective study was to investigate the impact of the ED approach on the prescription of psychotropic medication during inpatient psychiatric treatment.
METHODS: The clinical data of 1758 patients were analysed within a retrospective study design over a period of 12 years. ED level was assessed (1) for the first time (INITIAL-SEO), (2) during a previous hospital stay (PAST-SEO) or (3) not at all (NO-SEO). The effects of the ED assessment and the respective intervention during the current admission on the number of psychotropics and the number and dosage of antipsychotics were analysed for the total sample, including those with CB, autism spectrum disorders and psychosis. Group differences were analysed by a chi-square test and a one-factorial analysis of variance. For analysing the impact of the application of the ED approach on psychotropic medication, a covariance model was applied. Changes between the subsamples were analysed by t-tests for dependent samples.
RESULTS: The ED approach had a significant impact on reducing the overall amount of psychotropic medication and the dosage of antipsychotics in all patients with IDD. These effects were mainly attributable to those showing CB. In patients with autism spectrum disorders, the developmental approach reduced the number of antipsychotics. No effects could be observed in patients with psychosis; in this subsample, both the number and dosage of antipsychotics increased.
CONCLUSIONS: The application of the ED approach in the current hospital stay reduced the number of psychotropic drugs and the number and dosage of antipsychotics, especially in those patients with IDD and CB, but also in those with autism spectrum disorders.
The cerebrospinal fluid and intracranial pressure are two major reasons why central nervous system is so vulnerable to injuries. A composition and method for treating injured central nervous tissue, or preventing injury to central nervous system tissue is provided. The composition is comprised of a combination of colloidal osmotic agents and crystal osmotic agents. The method comprise of: a). Withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected and b). Injecting the composition which is dissolved by patient's own cerebrospinal fluid into subarachnoid spaces. The treatment can be augmented with agents that suppress production of cerebrospinal fluid, or with other known neuroprotective agents.
A formula, a system and a method is provided for treating urushiol induced contact dermatitis, chemical irritants and/or microbiological irritants on an affected area of skin of a user. The formula and/or the system is applied to an area of the skin of the user affected with urushiol, the chemical irritants and/or the microbiological irritants. The formula and/or the system have a cleansing agent, one or more surfactants and/or one or more abrasive agents for treating the urushiol induced contact dermatitis, the chemical irritants and/or the microbiological irritants. One or more abrasive agents separates the urushiol, the chemical irritants and/or the microbiological irritants from the skin of the user at the affected area. The cleansing agent bonds to the urushiol, the chemical irritants and/or the microbiological irritants at the affected area and withdraws the urushiol, the chemical irritants and/or the microbiological irritants from the tissue under the affected area of the skin of the user. The formula, the system, the urushiol, the chemical irritants and/or the microbiological irritants may be rinsed away from and/or may be removed from the affected area of the skin of the user. As a result, the urushiol induced contact dermatitis, the chemical irritants and/or the microbiological irritants is treated and/or is terminated by the formula, the system, the cleansing agent and/or one or more surfactants.
Over 100 million patients in the United States suffer from chronic pain. Chronic pain conditions are often debilitating, taking a toll on a patient's physical and mental welfare. Though a variety of pain management techniques currently exist, the most common nonsurgical options provide slow-acting and/or short-term relief. Medication, often in the form of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, comes with an array of side effects such as nausea and vomiting. Medication also presents the possibility of more serious effects such as increased risk of heart attack and stroke, and tolerance or dependency issues. Surgical strategies tend to be reserved for more severe cases and are limited by the risks and complications typically associated with surgery including bleeding, bruising, scarring, and infection. A nonsurgical, minimally invasive, long-lasting approach to chronic pain management is desirable.

Myoscience, Inc. (Redwood City, CA) has developed a pain management device - the Cryo-Touch III - for a novel, minimally invasive procedure using focused cold therapy to target sensory nerve tissue and offer long-lasting pain relief through cryoanalgesia. The device operates on the well-established cryobiology principle that localized exposure to controlled, moderately, low temperature conditions can alter tissue function. The therapy treats nerves via a probe in the form of an assembly of small diameter needles, creating a highly localized, low temperature treatment zone around the probe. This focused cold therapy creates a conduction block that prevents nerve signaling. Prior studies of the Cryo-Touch, Cryo-Touch II, Cryo-Touch III (a.k.a. PCP 1.0) devices have provided preliminary evidence of effectiveness on motor nerves and have been shown to be safe with no serious device-related adverse events.

Though studies have proven efficacious in targeting motor nerves, the device's effect on sensory nerves has yet to be investigated in the clinical setting. The goal of the study described herein is to evaluate the degree and duration of effect of the Cryo-Touch III in reducing chronic pain by targeting sensory nerves.
Embodiments of the present invention provide for assessing the state of an  82 Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of  82 Rb,  82 Sr, or  85 Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a  82 Sr/ 82 Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the  82 Rb elution system. Further, in response to determining that a total volume of the fluid exceeds a limit threshold, elution is prevented until the generator is replaced with a new generator.
The present invention discloses a method for preparing a traditional Chinese medicine for treating cough induced by common colds. Pinellia tuber is ground into powder, the pinellia tuber powder is steamed by the steam of an alum water solution, and the pinellia tuber powder is prepared after being taken out and dried in the sun. Basswood bark is ground into powder, then, the basswood bark powder is steamed by water steam, and the basswood bark powder is prepared after being taken out and dried in the sun. The mixed powder of the pinellia tuber powder and the basswood bark powder is prepared by mixing the pinellia tuber powder and the basswood bark powder. The mixed bile of chicken bile and ox bile is prepared by mixing chicken bile and ox bile. The mixed powder of the pinellia tuber powder and the basswood bark powder is soaked in the mixed bile of the chicken bile and the ox bile for a certain time, the traditional Chinese medicine for treating cough induced by common colds of the present invention is prepared by taking the mixed powder of the pinellia tuber powder and the basswood bark powder from the mixed bile of the chicken bile and the ox bile and drying the mixed powder in the shade. When the traditional Chinese medicine for treating cough induced by common colds, which is prepared by the method of the present invention, is used, cough is completely cured after administration several days, and cough does not relapse in two years. Compared with the traditional Chinese medicine for treating cough induced by common colds in the prior art, unexpected treatment effect is obtained.
A unique composition of material for manufacturing a cleansing cream has an excellent cleansing effect of greasy dirt, pigments and cosmetic residues from human skin. The basic composition of material of this invention to render the cleansing effect of greasy dirt, pigments and cosmetic residues from human skin is composed of ducks' fat oil and sodium carbonate, Na 2 CO 3 . The cleansing cream of this invention is excellent in cleansing greasy, viscous high molecular organic materials from not only human skin but also leathers, cloths, tiles, plastic and metal surfaces, by just pasting the cream and scrubbing. The cream can be wiped out with a tissue or cloth towel, rinsed with warm water. Alternatively, the cream can be allowed to stay on the skin and surface following the cleansing. The cleansing cream of this invention is non-toxic, non-allergic to human skin and environmentally affirmative. The cleansing cream of this invention is especially suitable for washing out of disguise pigments from a soldier's face.
Up to 300 hips globally will be implanted with a G7 Shell and either the Vivacit-E or Longevity Liner. The liner used by each site will be identified at start-up.
PROBLEM TO BE SOLVED: To produce an immunoliposome, capable of effectively and selectively transducing an antitumor active substance into a tumorous cell by bonding a cationic liposome membrane containing the antitumor active substance to a specific antibody selectively reactive with the tumorous cell. SOLUTION: This immunoliposome for transducing an antitumor active substance into a tumorous cell is obtained by bonding a cationic liposome membrane containing the antitumor active substance to a monoclonal antibody G-22 (antiCD 44 antibody) selectively reactive with the tumorous cell. A ceramide or an antiFas antibody capable of efficiently inducing apoptosis, a magnetite capable of manifesting hyperthermic effects and a gene effective in antitumor effects are preferred as the antitumor active substance. Dimethyldioctadecylammonium bromide and dioleylphosphatidylethanolamine are preferred as a lipid constituting the cationic liposome membrane. A cell of a glioma, a cell of melanoma, etc., which are cells excessively expressing CD44 are preferred as the tumorous cell to be an object of treatment. Furthermore, the daily dose of the immunoliposome for an adult is preferably 10-1000nmol expressed in terms of the amount of the lipid.
Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
Individual patients and study procedures. Entry criteria: gestational age between 24 weeks and 27 weeks + 6 days, babies born to mother with either clinical chorioamnionitis, preterm and prelabor rupture of the membranes (PPROM), or preterm labor, written informed consent obtained before inclusion and randomization. Exclusion criteria: babies born with birth weight below the 3th percentile, PPROM before 22 weeks, major fetal anomaly or congenital malformation, mother refusal or inability to provide consent. Stratification: stratum A: 24-25 weeks and stratum B: 26-27 weeks. Centrally controlled randomization takes place between 12 and 48 hours of age and patients assigned to the HC group are treated with 0,5 mg/kg HC intravenously twice a day for seven days and once a day for the next three days. Ibuprofen is only given to babies with persistent ductus arteriosis (PDA) echocardiographically confirmed at 24 hours of age or older.

Outcome variables. The primary outcome is a dichotomous variable: survival without BPD at 36 weeks PMA. A consistent physiologic definition of BPD will be used by all participating centres (Walsh MC, Pediatrics 2004;114:1305-11). Secondary outcome variables include features of WMI on MRI performed at 40 weeks PMA and neurodevelopmental outcome at 2-year of corrected age. Other outcome variables include death before discharge, BPD at 28 days and 36 weeks, duration of mechanical ventilation and O2 supplementation, need for vasopressors, use of open-labeled postnatal steroids (HC or dexamethasone), confirmed or suspected early and late onset sepsis, PDA, gastrointestinal perforation, NEC, ROP, IVH, biological markers of the neonatal inflammatory response syndrome.